25 January 2016

Prognostic value of Cardiopulmonary Exercise Testing in Heart Failure with preserved Ejection Fraction. The Henry Ford HospITal CardioPulmonary EXercise Testing (FIT-CPX) Project

Posted in Scientific News, Research News, Clinical CPET

indirect calorimetry

The American Heart Journal published a new article on the prognostic value of Cardio Pulmonary Exercise Test (CPX) in heart failure (HF) patients.

Although cardiopulmonary exercise testing in patients with heart failure and reduced ejection fraction (HFrEF) is well established, there is limited data on the value of CPX variables in patients with HF and preserved EF (HFpEF). The study sought to determine the prognostic value of select CPX measures in patients with HFpEF.

The study findings support the prognostic utility of peak VO2 and ppMVO2 in patients with HFpEF. The study can be purchased at the following link: click here


About COSMED

Founded in 1980, COSMED is a privately owned company manufacturing Cardio Pulmonary and Metabolic Diagnostic Equipment. COSMED products include a full range of Spirometers, Pulmonary Function, Body Composition, Nutritional Assessment and Cardio Pulmonary Exercise systems, including Electrocardiographs, Ergometers and Assessment Software. COSMED solutions are aimed for either professional or medical use for many different applications like: Hospital, Clinics, Primary Care, University & Education in Human Physiology, Clinical Nutrition, Commercial Weight Management, Human Performance Centers, Sport Institutions and Health Club Industry. COSMED Headquarters are located in the province of Rome, Italy. COSMED has subsidiaries in the USA, China and Germany, and distributes its products internationally through a constantly growing distributor network covering more than 70 countries.